Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Innovstone Therapeutics Limited is currently managing 2 pending office actions in the Biotechnology & Pharmaceuticals technology area. These 2 pending office actions are split between 2 distinct examiners, meaning each examiner is responsible for a single case. The applications are also located in 2 distinct art units, showing that the company's current prosecution efforts are focused on different technical areas within Biotechnology & Pharmaceuticals.
RZECZYCKI, PHILLIP MATTHEW is the busiest examiner, though he handles 1 pending office action. With 2 pending office actions and 2 distinct examiners, there is no overlap or concentration in the portfolio. Each of the applications must be prosecuted independently, as they are being reviewed by different people in 2 distinct art units. This distribution suggests a highly specific portfolio where each application represents a unique technical path. The 1 pending office action assigned to the busiest examiner reinforces the decentralized nature of the current filings. Practitioners should prepare for two separate sets of examiner expectations across the 2 distinct art units involved.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting only | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| RZECZYCKI, PHILLIP MATTHEW | 1 | 64.8% | +37.0% |
| WELLS, LAUREN QUINLAN | 1 | 49.4% | +59.7% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18720535 | AROMATIC HETEROCYCLE-SUBSTITUTED COMPOUNDS, AND PREPARATION METHOD THEREFOR AND USE THEREOF | WELLS, LAUREN QUINLAN | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19559874 | Substituted 2-(Pyrrolidine-3-yl)acetic Acid Derivative, Preparation Method and Use Thereof | RZECZYCKI, PHILLIP MATTHEW | — |
| 18720535 | AROMATIC HETEROCYCLE-SUBSTITUTED COMPOUNDS, AND PREPARATION METHOD THEREFOR AND USE THEREOF | WELLS, LAUREN QUINLAN | — |
| Art Unit | Apps |
|---|---|
| 1625 | 1 |
| 1622 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19559874 | Substituted 2-(Pyrrolidine-3-yl)acetic Acid Derivative, Preparation Method and Use Thereof | RZECZYCKI, PHILLIP MATTHEW | 1625 | DP | Final Rejection | — | Pending | Mar 06, 2026 |
| 18720535 | AROMATIC HETEROCYCLE-SUBSTITUTED COMPOUNDS, AND PREPARATION METHOD THEREFOR AND USE THEREOF | WELLS, LAUREN QUINLAN | 1622 | §102§103§112 | Non-Final OA | — | Pending | Jun 14, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialInnovstone Therapeutics Limited has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Phillip Matthew Rzeczycki has the most, with 1 of Innovstone Therapeutics Limited's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
